MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2

Ming Jenn Chen, De Wei Wu, Gao Chang Wang, Yao Chen Wang, Chi Yi Chen, Huei Lee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

MicroRNA-630 (miR-630) plays dual roles in tumor progression in various human cancers. However, the role of miR-630 in chemoresistance and prognosis in non-small cell lung cancer (NSCLC) remains to be elucidated. This retrospective study enrolled 114 surgically resected patients with NSCLC who experienced tumor relapse and underwent cisplatin-based chemotherapy. The aim was to examine the possible association between miR-630 (and its targeting of Bcl-2 expression) and the response to cisplatinbased chemotherapy. Patients with tumors expressing low miR-630, high Bcl-2, and a combination of both were more likely than their counterparts to show unfavorable responses to cisplatin-based chemotherapy. Kaplan-Meier and Cox regression analysis indicated that low miR-630, high Bcl-2, and a combination of both may independently predict poor overall survival and short relapse-free survival in patients with NSCLC. Six types of NSCLC cells were collected to determine the inhibitory concentration of cisplatin yielding 50% viability (IC50) by the MTT assay. The IC50 value for cisplatin was negatively correlated with miR-630 expression levels among these cell types, except for A549 cells. Mechanistically, low miR-630 expression conferred cisplatin resistance and colony formation by de-targeting Bcl-2 in NSCLC cells. We therefore suggest that low miR-630, high Bcl-2, and a combination of both may potentially predict an unfavorable chemotherapeutic response and poor outcome in patients with NSCLC.

Original languageEnglish
Pages (from-to)13758-13767
Number of pages10
JournalOncotarget
Volume9
Issue number17
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

MicroRNAs
Non-Small Cell Lung Carcinoma
Cisplatin
Drug Therapy
Inhibitory Concentration 50
Neoplasms
Recurrence
Survival
Retrospective Studies
Regression Analysis

Keywords

  • Bcl-2
  • Chemotherapy
  • Cisplatin
  • Micro-630
  • NSCLC

ASJC Scopus subject areas

  • Oncology

Cite this

MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2. / Chen, Ming Jenn; Wu, De Wei; Wang, Gao Chang; Wang, Yao Chen; Chen, Chi Yi; Lee, Huei.

In: Oncotarget, Vol. 9, No. 17, 01.01.2018, p. 13758-13767.

Research output: Contribution to journalArticle

Chen, Ming Jenn ; Wu, De Wei ; Wang, Gao Chang ; Wang, Yao Chen ; Chen, Chi Yi ; Lee, Huei. / MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2. In: Oncotarget. 2018 ; Vol. 9, No. 17. pp. 13758-13767.
@article{21e61087b0ac4fdb9c4e39976184ab60,
title = "MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2",
abstract = "MicroRNA-630 (miR-630) plays dual roles in tumor progression in various human cancers. However, the role of miR-630 in chemoresistance and prognosis in non-small cell lung cancer (NSCLC) remains to be elucidated. This retrospective study enrolled 114 surgically resected patients with NSCLC who experienced tumor relapse and underwent cisplatin-based chemotherapy. The aim was to examine the possible association between miR-630 (and its targeting of Bcl-2 expression) and the response to cisplatinbased chemotherapy. Patients with tumors expressing low miR-630, high Bcl-2, and a combination of both were more likely than their counterparts to show unfavorable responses to cisplatin-based chemotherapy. Kaplan-Meier and Cox regression analysis indicated that low miR-630, high Bcl-2, and a combination of both may independently predict poor overall survival and short relapse-free survival in patients with NSCLC. Six types of NSCLC cells were collected to determine the inhibitory concentration of cisplatin yielding 50{\%} viability (IC50) by the MTT assay. The IC50 value for cisplatin was negatively correlated with miR-630 expression levels among these cell types, except for A549 cells. Mechanistically, low miR-630 expression conferred cisplatin resistance and colony formation by de-targeting Bcl-2 in NSCLC cells. We therefore suggest that low miR-630, high Bcl-2, and a combination of both may potentially predict an unfavorable chemotherapeutic response and poor outcome in patients with NSCLC.",
keywords = "Bcl-2, Chemotherapy, Cisplatin, Micro-630, NSCLC",
author = "Chen, {Ming Jenn} and Wu, {De Wei} and Wang, {Gao Chang} and Wang, {Yao Chen} and Chen, {Chi Yi} and Huei Lee",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.24474",
language = "English",
volume = "9",
pages = "13758--13767",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "17",

}

TY - JOUR

T1 - MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2

AU - Chen, Ming Jenn

AU - Wu, De Wei

AU - Wang, Gao Chang

AU - Wang, Yao Chen

AU - Chen, Chi Yi

AU - Lee, Huei

PY - 2018/1/1

Y1 - 2018/1/1

N2 - MicroRNA-630 (miR-630) plays dual roles in tumor progression in various human cancers. However, the role of miR-630 in chemoresistance and prognosis in non-small cell lung cancer (NSCLC) remains to be elucidated. This retrospective study enrolled 114 surgically resected patients with NSCLC who experienced tumor relapse and underwent cisplatin-based chemotherapy. The aim was to examine the possible association between miR-630 (and its targeting of Bcl-2 expression) and the response to cisplatinbased chemotherapy. Patients with tumors expressing low miR-630, high Bcl-2, and a combination of both were more likely than their counterparts to show unfavorable responses to cisplatin-based chemotherapy. Kaplan-Meier and Cox regression analysis indicated that low miR-630, high Bcl-2, and a combination of both may independently predict poor overall survival and short relapse-free survival in patients with NSCLC. Six types of NSCLC cells were collected to determine the inhibitory concentration of cisplatin yielding 50% viability (IC50) by the MTT assay. The IC50 value for cisplatin was negatively correlated with miR-630 expression levels among these cell types, except for A549 cells. Mechanistically, low miR-630 expression conferred cisplatin resistance and colony formation by de-targeting Bcl-2 in NSCLC cells. We therefore suggest that low miR-630, high Bcl-2, and a combination of both may potentially predict an unfavorable chemotherapeutic response and poor outcome in patients with NSCLC.

AB - MicroRNA-630 (miR-630) plays dual roles in tumor progression in various human cancers. However, the role of miR-630 in chemoresistance and prognosis in non-small cell lung cancer (NSCLC) remains to be elucidated. This retrospective study enrolled 114 surgically resected patients with NSCLC who experienced tumor relapse and underwent cisplatin-based chemotherapy. The aim was to examine the possible association between miR-630 (and its targeting of Bcl-2 expression) and the response to cisplatinbased chemotherapy. Patients with tumors expressing low miR-630, high Bcl-2, and a combination of both were more likely than their counterparts to show unfavorable responses to cisplatin-based chemotherapy. Kaplan-Meier and Cox regression analysis indicated that low miR-630, high Bcl-2, and a combination of both may independently predict poor overall survival and short relapse-free survival in patients with NSCLC. Six types of NSCLC cells were collected to determine the inhibitory concentration of cisplatin yielding 50% viability (IC50) by the MTT assay. The IC50 value for cisplatin was negatively correlated with miR-630 expression levels among these cell types, except for A549 cells. Mechanistically, low miR-630 expression conferred cisplatin resistance and colony formation by de-targeting Bcl-2 in NSCLC cells. We therefore suggest that low miR-630, high Bcl-2, and a combination of both may potentially predict an unfavorable chemotherapeutic response and poor outcome in patients with NSCLC.

KW - Bcl-2

KW - Chemotherapy

KW - Cisplatin

KW - Micro-630

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=85042706635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042706635&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.24474

DO - 10.18632/oncotarget.24474

M3 - Article

AN - SCOPUS:85042706635

VL - 9

SP - 13758

EP - 13767

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 17

ER -